Key Takeaways
- Oscar Health (OSCR) shares climbed approximately 11% on Wednesday following CEO Mark Bertolini’s acquisition of 1 million shares at $11.92 each.
- The $11.92M stock purchase occurred through a private placement arrangement rather than through open-market trading — meaning the company issued fresh shares directly to its chief executive.
- Following this transaction, Bertolini’s total holdings reached 10.2M shares, giving him a 10.87% ownership stake in the health insurance company.
- The stock had previously gained approximately 7% on Tuesday after federal officials announced a 2.5% increase in Medicare Advantage reimbursement rates for 2027.
- Despite reporting $443.2M in net losses for 2025, Oscar projects 60% revenue expansion in 2026, forecasting between $18.7B and $19B in total revenue.
Oscar Health (OSCR) is currently trading at $14.43, representing a gain of $2.21 (+15.29%) as of the market opening.
Oscar Health’s CEO Mark Bertolini grabbed investor attention this week by purchasing 1 million shares of OSCR at $11.92 per share — an $11.92M commitment signaling confidence in the health insurer’s future trajectory. Shares responded with an approximately 11% surge Wednesday morning.
Regulatory filings disclosed after Tuesday’s closing bell revealed that Bertolini, the former Aetna CEO, executed the transaction on Monday, April 6.
However, this wasn’t a standard market purchase. The SEC Form 4 filing characterizes the deal as a private placement — indicating Oscar created 1 million new shares and sold them directly to Bertolini at $11.92, matching the closing price used that day for tax withholding on performance units that had vested.
Oscar received $11.92M in new funding from the arrangement, while Bertolini’s ownership position expanded to 10.87%, totaling 10,196,876 shares. The dilutive impact on existing shareholders remained limited.
Financial Performance and Outlook
Oscar’s 2025 results reveal a business experiencing rapid expansion while continuing to generate losses. Annual revenue reached $11.7B, advancing from $9.18B the previous year. Total membership hit an all-time high of 3.4 million. The company recorded net losses of $443.2M, alongside operating losses totaling $396.4M.
Looking ahead to 2026, management forecasts revenue between $18.7B and $19B — representing approximately 60% year-over-year expansion — while targeting a medical-loss ratio ranging from 82.4% to 83.4%. Wall Street analysts anticipate EPS of $0.77 for 2026, which would signal the company’s transition to profitability.
Those are ambitious objectives. Bertolini’s substantial personal investment indicates his confidence in achieving them.
For context, consider the industry leaders: UnitedHealth Group reported Q4 2025 revenue of $113.2B, reflecting 12.3% year-over-year growth. Centene and Molina Healthcare recorded single-digit percentage increases. Oscar’s expansion rate operates on an entirely different scale, despite profitability remaining elusive.
Understanding the Transaction Structure
It’s important to clarify what this transaction represents. A conventional open-market purchase — where an executive buys shares at prevailing market prices, absorbs trading costs, and immediately assumes downside risk — generally conveys a stronger bullish signal. That demonstrates: “I believe this price represents value today.”
A private placement follows different mechanics. Bertolini didn’t spontaneously place a market order. He acquired shares at a predetermined fair market value, as part of a structured transaction connected to equity vesting. The company secured capital; he increased his ownership.
Nevertheless, Bertolini had the option to liquidate vested shares for tax obligations and pocket the proceeds. Instead, he opted to expand his position. At current valuations, his Oscar holdings are worth approximately $125M.
OSCR shares had already advanced roughly 7% on Tuesday after federal authorities confirmed a 2.5% Medicare Advantage reimbursement rate increase for 2027 — exceeding the initial proposal to maintain flat rates.
Oscar’s Q1 2025 earnings release is scheduled for May 6 prior to market opening.
